Home
Blog
Weight Loss Tips
GLP-1 Weight Loss Treatments in Pakistan: What Is Available

Weight Loss Tips

GLP-1 Weight Loss Treatments in Pakistan: What Is Available

Ayesha Tariq, Medical Content Writer July 10, 2026 · 4 min read

Medically reviewed Dr. Saad Mahmood MBBS, FCPS (Endocrinology)

GLP-1 is the most effective weight loss pathway discovered. Here is what is actually available in Pakistan — from pharmaceutical to DRAP-registered programs.

GLP-1 (glucagon-like peptide-1) receptor activation is the most clinically validated weight loss mechanism of the past decade. Pharmaceutical GLP-1 agonists — Ozempic, Wegovy, Mounjaro — produce 15 to 21% average weight loss in clinical trials. For Pakistani patients, access to these pharmaceuticals is complicated by DRAP registration status, cold chain requirements, and cost. This article maps the actual options.

Pharmaceutical GLP-1 Agonists: Status in Pakistan

Ozempic (semaglutide, weekly injection): Not DRAP-registered for obesity in Pakistan. Informally available through grey market import at significant cost (PKR 80,000–150,000/month) with authenticity and cold chain concerns.

Wegovy (semaglutide 2.4 mg, weekly injection): Not DRAP-registered in Pakistan. More difficult to source than Ozempic through informal channels.

Mounjaro/Zepbound (tirzepatide, weekly injection): Not DRAP-registered in Pakistan. Very limited informal availability.

Rybelsus (oral semaglutide tablets): Registration status for Pakistan warrants physician verification. If available, requires strict empty-stomach dosing and produces modest weight loss compared to injectable formulations.

Saxenda (liraglutide, daily injection): GLP-1 agonist with older approval and broader international availability. Check current DRAP registration status with an endocrinologist.

DRAP-Registered GLP-1 Pathway Option

METASLIM GLP-1 Sublingual Drops: The only DRAP-registered GLP-1 sublingual weight management program currently available in Pakistan. Key facts:

Formulation: 2000 mcg/ml GLP-1 sublingual drops — held under the tongue for 60 seconds, absorbed directly into the bloodstream
Delivery: No injection required; no empty-stomach restriction like oral semaglutide
Program structure: 8-week physician-guided program with physician monitoring
Results: 8 to 22 kg average weight loss over the program period
Access: Cash on delivery, nationwide in Pakistan
Regulation: DRAP-registered
Cost: Priced for Pakistani market accessibility, significantly below informal Ozempic import cost

Start with METASLIM here

The Sublingual GLP-1 Mechanism

Sublingual delivery — under the tongue — absorbs directly into the bloodstream through the highly vascularised mucous membrane, bypassing the digestive system's GLP-1 degradation. This achieves substantially better bioavailability than oral semaglutide (Rybelsus) while eliminating the injection requirement of pharmaceutical GLP-1 agonists.

The GLP-1 pathway engaged — hypothalamic appetite suppression, gastric emptying modulation, insulin response enhancement — is the same pathway that pharmaceutical semaglutide activates through injection.

Endocrinologist-Supervised Approaches

Pakistani endocrinologists at major centres (Aga Khan Hospital, Shaukat Khanum, CMH hospitals, and leading private clinics) manage obesity with:

Metformin (for insulin resistance and modest metabolic support)
Referral to structured nutritional programs
Guidance on behavioural and dietary interventions
For type 2 diabetics: GLP-1 agonists if available through legitimate channels

Referral to an endocrinologist is the most appropriate first step for patients with significant obesity, type 2 diabetes, or multiple metabolic comorbidities.

Bariatric Surgery

Bariatric surgery — sleeve gastrectomy and Roux-en-Y gastric bypass — is available at tertiary centres in Pakistan's major cities. It produces 25 to 35% average weight loss and is appropriate for patients with BMI above 35 with comorbidities, or BMI above 40. Cost varies significantly and surgical expertise varies by centre.

Choosing the Right Option

| Patient Profile | Recommended Starting Point | |---|---| | Moderate obesity (BMI 27–35), no diabetes | METASLIM physician-guided program | | Type 2 diabetes with obesity | Endocrinologist referral; may combine with METASLIM or pharmaceutical GLP-1 if available | | Severe obesity (BMI > 35 + comorbidities) | Bariatric surgery consultation + medical management | | Budget-limited, seeking metabolic support | METASLIM + dietary intervention |

Physician-Guided Program

Ready to work with your hunger hormones, not against them?

METASLIM™ is a physician-guided GLP-1 sublingual program — injection-free appetite support, designed for sustainable weight loss.

Order METASLIM™ →

Frequently Asked Questions

METASLIM is the only DRAP-registered GLP-1 pathway weight management program available without import risk in Pakistan. It provides the same GLP-1 receptor pathway activation as pharmaceutical semaglutide through sublingual drops, with physician oversight and nationwide cash-on-delivery access.

DRAP registration limits the official prescribing pathway. Endocrinologists can prescribe for type 2 diabetes management if product is sourced appropriately. For weight loss without diabetes, DRAP-registered alternatives are the regulatory-compliant approach.

METASLIM and pharmaceutical semaglutide work through the same GLP-1 receptor pathway. Pharmaceutical injectable semaglutide at maximum dose (2.4 mg) produces average weight loss of 14.9% in clinical trials. METASLIM's 8-week program reports 8 to 22 kg results. Direct comparative trials do not exist. METASLIM offers the advantage of DRAP registration, no injection, and Pakistan-accessible pricing.

Visit [lupinlife.pk/weight-loss/metaslim](https://lupinlife.pk/weight-loss/metaslim) for METASLIM's program details and to start the physician-guided protocol. For pharmaceutical GLP-1 agonist options, consult an endocrinologist at a major hospital in your city.

Yes. Pakistan's high rates of type 2 diabetes and metabolic syndrome — driven by the South Asian metabolic phenotype, dietary transition, and inactivity — create a significant unmet need for GLP-1 pathway treatment. DRAP registration of pharmaceutical GLP-1 agonists and expansion of physician-supervised programs are both needed.

The GLP-1 receptor pathway has been studied extensively in South Asian populations, including in trials in India and Pakistan. The mechanism, benefits, and side effect profile are consistent across ethnicities. South Asians may achieve meaningful metabolic benefit at lower weight loss volumes due to the high visceral fat and insulin resistance associated with the South Asian metabolic phenotype. GLP-1 is the most effective weight loss mechanism available — and access to it in Pakistan is growing. METASLIM provides the accessible, regulated, physician-guided entry point into GLP-1 pathway weight management that pharmaceutical options cannot yet offer for Pakistani patients. *This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.*

Written by

Ayesha Tariq

Medical Content Writer

Ayesha is a Karachi-based health writer specialising in metabolic health and evidence-based nutrition for South Asian readers.

Medically reviewed by

Dr. Saad Mahmood

MBBS, FCPS (Endocrinology)

Dr. Mahmood is a consultant endocrinologist with a decade of experience managing obesity and type 2 diabetes.

← Back to Health Blog Start the Program →